tradingkey.logo
tradingkey.logo
Search

Ascentage Pharma Group International

AAPG
Add to Watchlist
17.425USD
-0.750-4.16%
Close 07-31 16:00ETQuotes delayed by 15 min
1.61BMarket Cap
--P/E TTM

Ascentage Pharma Group International

17.425
-0.750-4.16%

Shareholding Stats

Updated: Thu, Feb 19
Updated: Thu, Feb 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Point72 (DIFC) Ltd
0.02%
Point72 Asset Management, L.P.
0.02%
XY Capital Ltd.
0.01%
Citadel Advisors LLC
0.01%
Other
99.94%
Shareholders
Shareholders
Proportion
Point72 (DIFC) Ltd
0.02%
Point72 Asset Management, L.P.
0.02%
XY Capital Ltd.
0.01%
Citadel Advisors LLC
0.01%
Other
99.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.04%
Hedge Fund
0.03%
Other
99.93%

Institutional Shareholding

Updated: Sun, Apr 5
Updated: Sun, Apr 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
25
65.84K
0.07%
-220.96K
2025Q4
23
89.21K
0.29%
--
2025Q3
23
89.21K
0.29%
+6.09K
2025Q2
16
82.77K
0.27%
-154.43K
2025Q1
6
237.19K
0.00%
+237.19K

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Point72 (DIFC) Ltd
17.93K
0.02%
-2.96K
-14.17%
Sep 30, 2025
Point72 Asset Management, L.P.
16.73K
0.02%
+16.73K
--
Dec 31, 2025
XY Capital Ltd.
13.63K
0.01%
-4.49K
-24.79%
Dec 31, 2025
Citadel Advisors LLC
9.74K
0.01%
+85.00
+0.88%
Dec 31, 2025
ProFund Advisors LLC
5.11K
0.01%
+5.11K
--
Oct 31, 2025
Mirae Asset Global Investments (USA) LLC
2.55K
0%
+83.00
+3.37%
Dec 31, 2025
Geode Capital Management, L.L.C.
361.00
0%
--
--
Jan 31, 2026
Tower Research Capital LLC
230.00
0%
-599.00
-72.26%
Dec 31, 2025
Osaic Holdings, Inc.
220.00
0%
--
--
Dec 31, 2025
Parametric Portfolio Associates LLC
153.00
0%
-50.00
-24.63%
Dec 31, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
0.43%
Invesco Golden Dragon China ETF
0%
Tema Oncology ETF
Proportion0.43%
Invesco Golden Dragon China ETF
Proportion0%
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.